

7 March 2025

Notice of Annual General Meeting

AstraZeneca PLC (the Company) announced today the publication of its Notice of Annual General Meeting 2025 and Shareholders' Circular (the Notice).

The Company's Annual General Meeting (AGM) will be digitally-enabled and will be held on Friday 11 April 2025 at 14:30 (BST). Full details and joining instructions are set out in the Notice.

The Notice and proxy form for the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at <https://data.fca.org.uk/#/nsm/nationalstoragemechanism>. The Notice is also available on the Company's website at www.astrazeneca.com/noticeofmeeting2025.

The Notice is being despatched to shareholders today.

The business to be conducted at the AGM is summarised below:

1. To receive the Company's Accounts, the Reports of the Directors and Auditor and the Strategic Report for the year ended 31 December 2024
2. To confirm the 2024 interim dividends
3. To re-appoint PricewaterhouseCoopers LLP as Auditor
4. To authorise the Directors to agree the remuneration of the Auditor
5. To elect or re-elect Directors
6. To approve the annual statement of the Chair of the Remuneration Committee and the Annual Report on Remuneration for the year ended 31 December 2024
7. To authorise limited political donations
8. To authorise the Directors to allot shares
9. To authorise the Directors to disapply pre-emption rights
10. To authorise the Directors to further disapply pre-emption rights for acquisitions and specified capital investments
11. To authorise the Company to purchase its own shares
12. To reduce the notice period for general meetings

Pursuant to Regulation 41 of the Uncertificated Securities Regulations 2001, only holders of ordinary shares entered in the register of members of the Company by 18:30 (BST) on 9 April 2025 (or their duly appointed proxies), or if this meeting is adjourned, in the register of members by 18:30 (BST) two days prior to any adjourned meeting, are entitled to attend or vote at the AGM in respect of the number of ordinary shares registered in their name at that time. Changes to the entries in the register of members after 18:30 (BST) on 9 April 2025, or if this meeting is adjourned, in the register of members after 18:30 (BST) two days prior to any adjourned meeting, shall be disregarded in determining the rights of any person to attend or vote at the AGM. The Record Date applied to the Euroclear Sweden system to determine entitlement to participate and vote at the AGM is close of business on 2 April 2025. The Record Date to determine entitlement to participate and vote at the AGM for registered holders of the

Record Date to determine entitlement to participate and vote at the AGM for registered holders of the Company's American Depositary Receipts is close of business on 25 February 2025.

[AstraZeneca](#)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media [@AstraZeneca](#)

Contacts

For details on how to contact the Investor Relations Team, please click [here](#). For Media contacts, click [here](#).

Adrian Kemp
Company Secretary
AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NOAUPURCWUPAGUM